The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
EBSCO
DOI Registration Agency (USA)

Epidemiological aspects of sarcopenia in patients with rheumatic diseases

DOI: https://doi.org/10.29296/25877305-2020-10-08
Issue: 
10
Year: 
2020

Yu. Lavrishcheva(1), A. Yakovenko(2), Candidate of Medical Sciences (1)V.A. Almazov National
Medical Research Center, Ministry of Health of Russia, Saint Petersburg (2)Acad. I.P. Pavlov First Saint
Petersburg State Medical University, Ministry of Health of Russia

The aim of the study. To assess the prevalence of sarcopenia in rheumatological patients. Patients and methods. 317 patients with rheumatological pathology were examined, among them 201 women and 116 men, the age of patients ranged from 21 to 58 years, the average age at the time of inclusion of patients in the study was 41.1±7.3 years. Sarcopenia was diagnosed using the method recommended by The European Working Group on Sarcopenia in Older People 2. Results. The frequency of occurrence of a decrease in the total mass of skeletal muscle according to the skeletal muscle mass index (ISMM) was 31.2% (n=99), a decrease in muscle strength according to the wrist dynamometry was observed in 44.5% (n=141), low skeletal muscle performance according to the results NIH Toolbox 4 Meter Walk Gait Speed Test in 42.8% (n=135). The prevalence of suspected sarcopenia (probable sarcopenia) was 13.3% (n=42) and sarcopenia 31.2% (n=99), no cases of severe sarcopenia were detected. Statistically significant differences were obtained between groups of patients depending on the duration of rheumatological disease and the prevalence of sarcopenia (χ2=19.328; p=0.001). Conclusion. The prevalence of sarcopenia in rheumatological patients in the general population was 31.2%.

Keywords: 
rheumatology
prevalence
sarcopenia
rheumatological diseases



References: 
  1. Cruz-Jentoft A.J., Bahat G., Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48 (1): 16–31. DOI: 10.1093/ageing/afy169
  2. Cruz-Jentoft A.J., Sayer A.A. Sarcopenia. Lancet. 2019; 393 (10191): 2636–46. DOI: 10.1016/S0140-6736(19)31138-9
  3. Mijnarends D.M., Koster A., Schols J.M. et al. Physical activity and incidence of sarcopenia: the population-based AGES-Reykjavik Study. Age Ageing. 2016; 45 (5): 614–20. DOI: 10.1093/ageing/afw090
  4. Cederholm T., Jensen G.L., Correia M. et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clin Nutr. 2019; 38 (1): 1–9. DOI: 10.1016/j.clnu.2018.08.002
  5. Ngeuleu A., Allali F., Medrare L. et al. Sarcopenia in rheumatoid arthritis: Prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017; 37: 1015–20. DOI: 10.1007/s00296-017-3665-x
  6. Torii M., Hashimoto M., Hanai A. et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2018; 11: 1–7. DOI: 10.1080/14397595.2018.1510565
  7. El Maghraoui A., Ebo’o F.B., Sadni S. et al. Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosing spondylitis? BMC Musculoskelet Disord. 2016; 17: 268. DOI: 10.1186/s12891-016-1155-z
  8. Krajewska-Włodarczyk M., Owczarczyk-Saczonek A., Placek W. Changes in body composition and bone mineral density in postmenopausal women with psoriatic arthritis. Reumatologia. 2017; 55: 215–21. DOI: 10.5114/reum.2017.71627
  9. Human Energy Requirements: Report of a Joint FAO/WHO/UNU Expert Consultation. [(accessed on 5 November 2018)]; Available online: http://www.fao.org/3/a-y5686e.pdf
  10. Barone M., Viggiani M.T., Anelli M.G. Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. J Clin Med. 2018; 7 (12): pii: E504. DOI: 10.3390/jcm7120504
  11. Polyzos S.A., Margioris A.N. Sarcopenic obesity. Hormones (Athens). 2018; 17 (3): 321–31. DOI: 10.1007/s42000-018-0049-x